Suppr超能文献

抗凝血丝氨酸蛋白酶抑制剂:止血和血栓形成的内源性调节因子。

Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

作者信息

Grover Steven P, Mackman Nigel

机构信息

Division of Hematology and Oncology, Department of Medicine, UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

出版信息

Front Cardiovasc Med. 2022 May 3;9:878199. doi: 10.3389/fcvm.2022.878199. eCollection 2022.

Abstract

Appropriate activation of coagulation requires a balance between procoagulant and anticoagulant proteins in blood. Loss in this balance leads to hemorrhage and thrombosis. A number of endogenous anticoagulant proteins, such as antithrombin and heparin cofactor II, are members of the serine protease inhibitor (SERPIN) family. These SERPIN anticoagulants function by forming irreversible inhibitory complexes with target coagulation proteases. Mutations in SERPIN family members, such as antithrombin, can cause hereditary thrombophilias. In addition, low plasma levels of SERPINs have been associated with an increased risk of thrombosis. Here, we review the biological activities of the different anticoagulant SERPINs. We further consider the clinical consequences of SERPIN deficiencies and insights gained from preclinical disease models. Finally, we discuss the potential utility of engineered SERPINs as novel therapies for the treatment of thrombotic pathologies.

摘要

凝血的适当激活需要血液中促凝蛋白和抗凝蛋白之间的平衡。这种平衡的丧失会导致出血和血栓形成。许多内源性抗凝蛋白,如抗凝血酶和肝素辅因子II,都是丝氨酸蛋白酶抑制剂(SERPIN)家族的成员。这些SERPIN抗凝剂通过与目标凝血蛋白酶形成不可逆的抑制复合物来发挥作用。SERPIN家族成员(如抗凝血酶)的突变可导致遗传性血栓形成倾向。此外,SERPINs血浆水平低与血栓形成风险增加有关。在这里,我们综述了不同抗凝SERPINs的生物学活性。我们进一步考虑了SERPIN缺乏的临床后果以及从临床前疾病模型中获得的见解。最后,我们讨论了工程化SERPINs作为治疗血栓性疾病的新型疗法的潜在效用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验